Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and multiple sclerosis. The ARCUS technology platform allows for delivery of medication through inhalation. It has been used in clinical trials across a broad spectrum of applications: local and systemic disease targets, large and small molecules, and a wide range of doses. The Company has two clinical-stage programs that use the ARCUS technology: CVT-301 (symptoms of OFF periods in Parkinson’s disease) and CVT-427 (acute treatment of migraine).